胸腺肽肠溶片联合复方硫酸软骨素治疗类风湿性关节炎的临床研究

目的探讨胸腺肽肠溶片联合复方硫酸软骨素治疗类风湿性关节炎的临床疗效。方法选取2015年5月—2016年5月南阳市骨科医院收治的类风湿性关节炎患者90例,随机分为对照组和治疗组,每组各45例。对照组口服复方硫酸软骨素片,4片/次,3次/d。治疗组在对照组的基础上口服胸腺肽肠溶片,2片/次,3次/d。两组患者治疗时间均为3个月。评价两组患者临床疗效,同时比较治疗前后两组患者临床症状、关节炎相关指标和免疫球蛋白水平。结果治疗后,对照组和治疗组总有效率分别为80.00%和93.33%,两组比较差异具有统计学意义(P0.05)。治疗后,两组肿胀关节数、压痛关节数和晨僵时间均出现明显下降,握力则明显升高,同组比较差异具有统计学意义(P0.05)。且治疗组这些临床症状则明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者类风湿因子(RF)、血沉(ESR)和C反应蛋白(CRP)水平均显著降低(P0.05)。且治疗组上述关节炎相关指标均明显低于对照组(P0.05)。治疗后,两组患者IgG、IgA及IgM均明显降低(P0.05);且治疗组上述指标含量明显低于对照组(P0.05)。结论胸腺肽肠溶片联合复方硫酸软骨素治疗类风湿性关节炎临床疗效确切,具有一定的临床推广应用价值。

Clinical study on Thymopdypeptide Enteric-Coated Tablets combined with compound chondroitin sulfate in treatment of rheumatoid arthritis

Objective To explore the clinical effects of Thymopdypeptide Enteric-Coated Tablets combined with compound chondroitin sulfate in treatment of rheumatoid arthritis. Methods Patients (90 cases) with rheumatoid arthritis in Nanyang Orthopedic Hospital from May 2015 to May 2016 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were po administered with Compound Chondroitin Sulfate Tablets, 4 tablets/time, three times daily. Patients in the treatment group were po administered with Thymopdypeptide Enteric-Coated Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 3 months. After treatment, clinical efficacy was evaluated, and the clinical symptoms, arthritis indexes, and immunoglobulin content in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.00% and 93.33%, respectively, and there were differences between two groups (P<0.05). After treatment, the tender and swollen joints, and morning stiffness time in two groups were significantly decreased, but the gripping force was significantly increased, the difference was statistically significant in the same group (P<0.05). And these clinical symptoms in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the RF, ESR and CRP levels in two groups were significantly decreased (P<0.05). And these arthritis indexes in the treatment group were obviously lower than those in the control group (P<0.05). After treatment, the IgG, IgA, and IgM in two groups were significantly decreased (P<0.05). And the immunoglobulin content in the treatment group was obviously lower than that in the control group (P<0.05). Conclusion Thymopdypeptide Enteric-Coated Tablets combined with compound chondroitin sulfate has a good clinical curative effect in treatment of rheumatoid arthritis, which has a certain clinical application value.